DRAXIS EXTENDS SCHEDULED SHUTDOWN FOR CONTRACT MANUFACTURING DIVISION

DRAXIS Health Inc. (TSX: DAX) (Nasdaq: DRAX) has extended the period before it will resume production of sterile and lyophilized products at DRAXIS Pharma, its pharmaceutical contract manufacturing division, as part of its regular summer shutdown for maintenance. This extended shutdown does not affect in any way its production of non-sterile products or radiopharmaceutical products sold by the DRAXIMAGE division. The shutdown period for the sterile and lyophilized product areas was initially scheduled to run for two to three weeks, but due to additional requirements that came to light near the end of the initial shutdown period, it is now expected that the shutdown will be five to seven weeks in total.

CNW Telbec (http://www.cnw.ca/fr/releases/archive/August2005/26/c3540.html)